VitriVax Secures $87 Million Series C Funding to Advance Lyme Disease Vaccine Candidate into Clinical Development and Expand Pipeline

VitriVax Raises $87 Million in Oversubscribed Series C Financing to Advance Lyme Disease Vaccine and Expand ALTA® Technology Pipeline

VitriVax, a vaccine development and formulation technology company, has announced the successful close of an oversubscribed $87 million Series C financing round. The investment will support the advancement of the company’s lead Lyme disease vaccine candidate toward its first-in-human clinical trial and enable further expansion of its pipeline of vaccine candidates developed using its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology platform.

The financing was co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures. Eli Lilly and Company also participated in the round, alongside other existing investors. The oversubscribed financing reflects continued investor interest in VitriVax’s vaccine development strategy and the potential applications of its ALTA® platform across different vaccine technologies and disease areas.

The company plans to use the proceeds to move beyond its technology development and partnership activities toward a broader portfolio of proprietary vaccine programs. Its immediate priorities include generating first-in-human clinical data for its Lyme disease candidate, expanding its internally developed pipeline and continuing collaborations with global health organizations to improve vaccine accessibility.

Romulo Colindres, Chief Executive Officer of VitriVax, said the strong demand for the financing and the participation of established investors demonstrate growing confidence in the company’s technology and lead vaccine candidate.

“The strong demand for this financing round and the caliber of investors who joined it reflect growing conviction in our ALTA® platform and in our Lyme disease vaccine candidate,” Colindres said.

He added that the financing represents an important transition for VitriVax as it develops its own vaccine portfolio while continuing to support global health initiatives.

“This financing marks VitriVax’s transition into a vaccine development company with its own pipeline. Our priorities now are to generate first-in-human data for our Lyme disease candidate, and build a portfolio of proprietary programs, while continuing our work with global health partners to bring better vaccines to the people who need them most,” he said.

Lyme Disease Vaccine Program Becomes Company’s Lead Development Priority

VitriVax’s Lyme disease vaccine candidate is the company’s lead proprietary program and a central focus of the newly secured financing. Lyme disease is the most common vector-borne disease in the United States and Europe, and its geographic distribution continues to expand. The disease is transmitted through infected ticks and can lead to significant health consequences if infection is not identified and treated appropriately.

Despite the growing public health burden, there is currently no approved human vaccine for Lyme disease. Vaccine developers have continued to investigate potential preventive approaches, but late-stage candidates in development rely on multi-dose primary vaccination schedules followed by booster doses before each tick season.

Such schedules can create challenges for vaccination programs and individual patients. Completing multiple doses and returning for subsequent boosters require time, access to healthcare services and continued adherence to recommended schedules. Across vaccines, as many as 50% of patients fail to complete rigorous multi-dose regimens, potentially reducing the effectiveness of vaccination programs in real-world settings.

VitriVax is developing its Lyme disease candidate with the goal of providing broad protection against infection while potentially simplifying the vaccination process. The company’s approach is designed to support single-dose administration, which could reduce the practical challenges associated with multi-dose schedules and help improve completion rates.

A vaccine that offers broad protection with a more convenient administration schedule could have meaningful implications for people living in regions where Lyme disease is prevalent or expanding. It may also offer advantages for healthcare providers and public health organizations responsible for implementing vaccination programs.

The company believes its candidate has the potential to become a differentiated option in the Lyme disease vaccine market. However, its clinical performance and safety profile will need to be established through human clinical studies. The planned first-in-human trial represents an important next step in evaluating the candidate and generating initial clinical evidence.

ALTA® Platform Designed to Improve Vaccine Formulation and Delivery

The ALTA® technology platform is the foundation of VitriVax’s vaccine development strategy. The platform uses atomic-layering technology to stabilize vaccine antigens and adjuvants, with the objective of improving vaccine formulation, immune response and product stability.

One of its central capabilities is the potential to support single-dose vaccine administration. Conventional vaccine development may require multiple doses to generate and maintain an adequate immune response. VitriVax’s approach is intended to address this limitation by enabling formulations designed to deliver a more effective immune response through a simplified schedule.

Beyond dosing convenience, ALTA® is designed to generate a balanced immune response. Insufficient immunogenicity, or the inability of a vaccine to stimulate a strong enough immune response, is one of the leading causes of vaccine failure in clinical trials. By improving the way antigens and adjuvants are formulated and delivered, VitriVax aims to address this challenge across its vaccine development programs.

The platform may also offer antigen- and adjuvant-sparing capabilities. This means that vaccine formulations could potentially achieve their intended effects while using lower quantities of these components. Reducing the amount of antigen or adjuvant required could have several potential benefits, including decreased reactogenicity and lower manufacturing costs.

Reactogenicity refers to short-term reactions that can occur following vaccination. A formulation that requires smaller quantities of certain components may help reduce these reactions, although the actual safety and tolerability profile would need to be assessed for each individual vaccine candidate through appropriate testing.

Lower component requirements could also contribute to improved manufacturing economics. By potentially reducing the quantities of materials needed per dose, the technology may support more efficient production and help lower the cost of goods. These capabilities could be particularly valuable when developing vaccines intended for large populations or global health programs.

Extending ALTA® to mRNA Vaccine Delivery

VitriVax has also expanded the application of its ALTA® platform to a novel mRNA delivery system that does not require lipid nanoparticles (LNPs).

Lipid nanoparticles are commonly used in mRNA vaccine technologies to help deliver genetic instructions into cells. Although they have played an important role in the development of mRNA vaccines, formulation and delivery requirements can introduce additional manufacturing and storage considerations.

VitriVax’s LNP-free approach is intended to explore an alternative method of delivering mRNA while applying the stabilization principles of its ALTA® technology. The company believes this could broaden the platform’s potential applications beyond traditional protein-based and glycoconjugate vaccine formats.

The ability to work across protein, glycoconjugate and mRNA modalities could provide VitriVax with opportunities to develop vaccine candidates for a wider range of infectious diseases. It also creates the possibility of applying common formulation and stabilization capabilities to different types of vaccine products.

Another important feature of the ALTA® platform is its potential to reduce dependence on conventional cold-chain requirements. Many vaccines require tightly controlled temperature conditions during storage and transportation to preserve product quality. Maintaining these conditions can be difficult in regions with limited refrigeration infrastructure or unreliable electricity supplies.

By stabilizing antigens and adjuvants, ALTA® is designed to improve vaccine thermostability and reduce cold-chain dependence. This could support distribution in resource-limited settings and help global health organizations reach communities where maintaining conventional vaccine storage conditions is challenging.

The company sees this capability as an important part of its broader objective to develop vaccines that are not only effective but also practical to manufacture, distribute and administer.

Pipeline Expansion Across Multiple Infectious Diseases

Building on its Lyme disease program, VitriVax is assembling a pipeline of vaccine candidates targeting indications where single-dose administration and improved immunogenicity could provide meaningful clinical and commercial advantages.

The company’s development strategy combines wholly owned product candidates with programs supported through strategic collaborations and global health partnerships. This model is intended to create multiple sources of long-term value while allowing the company to apply its formulation technology to a broad range of vaccine development challenges.

VitriVax’s research and development activities include programs in rabies, melioidosis, polio and HIV. These initiatives address infectious diseases with different biological characteristics and public health requirements, providing opportunities to assess the versatility of ALTA® across multiple vaccine applications.

The rabies vaccine program has received support from the Coalition for Epidemic Preparedness Innovations (CEPI). The collaboration reflects the potential relevance of improved vaccine formulation and delivery technologies to global health priorities.

The company’s melioidosis program has received support through the Defense Threat Reduction Agency (DTRA), including a U.S. Department of Defense contract. Melioidosis is an infectious disease that represents a public health concern in certain regions, and vaccine development efforts could benefit from technologies that improve immunogenicity and practical administration.

VitriVax is also advancing polio and HIV vaccine-related programs with support from the Gates Foundation. These partnerships provide opportunities to explore the application of ALTA® technology in areas where improved vaccine access and delivery could have substantial public health importance.

Through these programs, VitriVax is pursuing both proprietary development opportunities and collaborations with organizations focused on addressing infectious diseases worldwide.

Manufacturing Readiness Supports Clinical Development

In addition to advancing its vaccine candidates, VitriVax has made progress toward current Good Manufacturing Practice (cGMP) manufacturing readiness for Phase 1 clinical trials.

Manufacturing readiness is an important requirement for moving experimental vaccine candidates into human studies. Clinical trial materials must be produced under appropriate quality systems and manufacturing controls to support the evaluation of safety and other clinical characteristics.

The company’s progress in this area is intended to support the transition of its lead Lyme disease candidate toward first-in-human testing. As the program approaches clinical development, manufacturing capabilities will remain an important component of its execution strategy.

The Series C funding is expected to provide resources for these activities while supporting the continued development of additional candidates based on the ALTA® platform.

Investors Highlight Potential of the ALTA® Technology

The participation of major life sciences investors and industry organizations highlights the interest in VitriVax’s approach to vaccine development and delivery.

Chris Gagliardi, Principal at Sanofi Ventures, said innovation in vaccine development could improve how vaccines are designed, manufactured and used.

“We believe innovation in vaccine development and delivery has the potential to improve how vaccines are designed, manufactured, and ultimately used. VitriVax’s ALTA® platform brings together several compelling capabilities into one differentiated approach, and we are excited to support the team as they advance the technology and explore its potential across a broader range of applications,” Gagliardi said.

His comments reflect the potential of a platform that combines multiple formulation capabilities, including the possibility of single-dose administration, improved immune responses, reduced component requirements and greater thermostability.

Mario Barro, Head of Infectious Diseases and Venture Partner at RA Capital, emphasized the need for a convenient and effective Lyme disease vaccine.

“We need a safe, effective, and convenient Lyme vaccine to prevent millions of people from suffering the dangerous, chronic, and painful ramifications of this increasingly common disease,” Barro said.

He added that RA Capital is pleased to continue supporting VitriVax as it advances its Lyme disease program and develops ALTA® for different vaccine technologies.

“We are proud to continue to support Vitrivax as it advances this unique program and continues to develop its ALTA® platform, a potentially game-changing technology across protein/glycoconjugate and mRNA modalities,” he said.

Muzammil Mansuri, Venture Partner at F-Prime, also highlighted the importance of vaccine accessibility and ease of use in real-world healthcare settings.

“Vaccines have the power to truly impact lives when they are accessible and easy to use in real-world settings. VitriVax’s approach eliminates traditional barriers – complex dosing and cold chain hurdles – so more people can benefit,” Mansuri said.

He added that F-Prime is proud to support the company as it advances solutions intended to provide practical benefits for patients and healthcare providers.

Series C Builds on Earlier Financing and Global Health Support

The $87 million Series C financing builds on VitriVax’s $17.25 million Series B round, which was completed in September 2025. The company has also received non-dilutive funding and development support from organizations including the Gates Foundation, CEPI and the U.S. Department of Defense.

Since completing its Series B financing, VitriVax has advanced its Lyme disease vaccine program toward clinical development while continuing partner- and grant-funded projects in rabies, melioidosis, polio and HIV. It has also progressed cGMP manufacturing readiness to support Phase 1 clinical trials.

The combination of private investment, strategic partnerships and non-dilutive funding has helped the company advance its technology and broaden its development activities.

Advancing a Broader Vaccine Development Strategy

With the close of its oversubscribed $87 million Series C, VitriVax is entering a new phase focused on translating its technology platform into a growing portfolio of vaccine candidates. The company’s immediate objective is to advance its lead Lyme disease program into first-in-human testing and generate clinical data that can inform subsequent development.

At the same time, VitriVax plans to expand ALTA® applications across protein, glycoconjugate and mRNA vaccine technologies. Its focus on single-dose administration, balanced immune responses, reduced antigen and adjuvant requirements, and improved thermostability reflects an effort to address several longstanding challenges in vaccine development.

The company’s combination of proprietary programs and global health partnerships is intended to support both commercial opportunities and broader public health objectives. As development progresses, clinical studies and further research will be necessary to establish whether the platform’s potential advantages translate into measurable benefits for individual vaccine candidates.

The new financing provides VitriVax with additional resources to pursue these priorities and continue developing vaccine technologies designed to improve how vaccines are formulated, manufactured, delivered and used around the world.

About VitriVax

VitriVax, headquartered in Boulder, Colorado, is a vaccine development and formulation technology company advancing a pipeline of proprietary vaccine candidates built on its Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform. The company’s lead program is a single-dose Lyme disease vaccine candidate with a novel mechanism of action and best-in-class potential.

ALTA® is designed to improve immunogenicity, enable single-dose administration, spare antigen and adjuvant, confer thermostability, and deliver mRNA without the need for LNPs. VitriVax collaborates with the Gates Foundation, CEPI, and the U.S. Department of Defense on programs that advance global health and preparedness, reflecting the company’s ongoing commitment to expanding access to vaccines worldwide. 

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter